Welcome to our dedicated page for Lite Strategy SEC filings (Ticker: LITS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lite Strategy, Inc. filings document the company’s public-company transition, operating results, Litecoin treasury strategy, and capital-allocation actions. Form 8-K disclosures include furnished financial results, the board-authorized common stock repurchase program, and equity securities activity tied to pre-funded warrants issued in a private placement.
The filings also cover governance and compensation matters, including annual meeting voting results, director elections and resignation, executive appointment to chief executive officer and the board, stock option grants, and approval of the 2026 Omnibus Equity Compensation Plan. SEC reports identify MEI Pharma, Inc. as the company’s former name and support the current Lite Strategy identity.
MEI Pharma, Inc. filed a shelf registration on Form S-3 that describes the company's capitalization and resale mechanics for existing holders. The filing discloses $0.00000002 par value for each of up to 226,000,000 shares of common stock and 100,000 shares of undesignated preferred stock. As of June 30, 2025, 102,513 common shares are issuable upon exercise of warrants at $6.80 per share, 869,168 shares are issuable upon exercise of options with a weighted-average exercise price of $32.85, 920,737 shares are reserved under the 2008 Omnibus Plan, and 169,698 shares are reserved under the 2021 Inducement Plan. The filing lists a range of permitted sale methods for selling stockholders including brokerage, block trades, privately negotiated transactions, option/hedging arrangements, and other lawful methods. It also describes a three-year restriction on certain transfers by any stockholder who becomes an interested stockholder (owner of 15% or more voting stock) unless specific board approvals or exceptions apply. The filing cross-references the company’s Annual Report for the fiscal year ended June 30, 2025 and several Current Reports filed in July–September 2025.
Lite Strategy, Inc. (LITS) director Lee Charles Benjamin received a non‑derivative grant of 10,000 stock options on 10/03/2025 with an exercise price of $2.56. The option is a stock option exercisable into 10,000 shares of common stock and expires on 10/03/2035. The grant vests in 36 equal monthly installments, with the first monthly installment vesting one month after the grant, subject to continued service through each vesting date. Following the reported transaction the reporting person is shown as beneficially owning the 10,000 underlying shares on a direct basis. The filing was submitted under power of attorney by Justin J. File and dated 10/06/2025.
Flynn James P, a director of Lite Strategy, Inc. (ticker LITS), reported a purchase of 10,000 shares of the company's common stock on 09/30/2025. The filing shows a weighted-average purchase price of $2.543 per share, with individual transactions priced between $2.51 and $2.58. After the acquisition, Flynn beneficially owned 17,900 shares.
The Form 4 was submitted on 10/02/2025 and signed by an attorney-in-fact. The reporting person offers to provide details on the split of share counts by price within the disclosed range upon request.
Lite Strategy, Inc. (filing excerpts) discloses equity plan details, leadership changes, executive pay and severance terms, option activity, license and contingent payment obligations, and committee responsibilities. The company has omnibus and inducement equity plans authorizing 1,850,739 and 217,000 shares respectively, with specific option pools and weighted-average exercise prices reported. Leadership changes included resignations of the CEO and CMO effective August 1, 2024, with separation agreements providing severance, COBRA and accelerated vesting; one former CEO received $614,000 severance. Justin J. File became Acting CEO (in addition to CFO) and received total annual compensation of $912,667 and a $275,000 annual incentive plus a $96,000 success fee tied to cash retention. The filing notes cashless exercises and warrant conversions totaling millions of shares issued and lists committee charters and oversight duties for audit, compensation and nominating committees.
Lite Strategy, Inc. reported that an investor exercised a portion of previously issued pre-funded warrants. These warrants were originally issued on July 22, 2025 in a private PIPE offering at an offering price of $3.4199 per pre-funded warrant for up to 6,022,869 shares of common stock.
On September 10, 2025, the investor exercised 1,595,000 pre-funded warrants in a cashless transaction, receiving 1,594,944 shares of Lite Strategy common stock. The warrants and the shares issued upon exercise were issued in transactions relying on private offering exemptions under Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D.